PDCO
74
-3
SPG
53
2
PVH
60
2
APH
62
-3
CA
25
-7
A
39
-2
MCO
74
-3
KMX
66
-2
FLS
69
-2
IR
55
-3
FOX
68
-2
TJX
64
-4
TXN
39
3
KR
57
-6
SRE
47
2
FSLR
63
5
NWSA
73
-2
JPM
59
-3
PHM
53
-4
AN
50
-5
PDCO
74
-3
SPG
53
2
PVH
60
2
APH
62
-3
CA
25
-7
A
39
-2
MCO
74
-3
KMX
66
-2
FLS
69
-2
IR
55
-3
FOX
68
-2
TJX
64
-4
TXN
39
3
KR
57
-6
SRE
47
2
FSLR
63
5
NWSA
73
-2
JPM
59
-3
PHM
53
-4
AN
50
-5
Financhill
Back

Avalo Therapeutics 10K Form

Sell
31

AVTX
Avalo Therapeutics

Last Price:
9.30
Seasonality Move:
10.12%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AVTX News And Ratings

See the #1 stock for the next 7 days that we like better than AVTX

AVTX Financial Statistics

Sales & Book Value

Annual Sales: $1.92M
Cash Flow: $-11.53M
Price / Cash Flow: 0
Annual Sales: $2.18
Price / Book: 4.58

Profitability

EPS (TTM): -3530.81780
Net Income (TTM): $-7.96M
Gross Margin: $640K
Return on Equity: 0%
Return on Assets: -10.45%

Avalo Therapeutics Earnings Forecast

Key Avalo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 9 years for AVTX is 33.26%.
  • The Selling, General & Administrative Expenses for AVTX have been equal to 535.34% of Gross Profit Margin.
  • The Research & Development expenses have been 716.42% of Revenue.
  • The Interest Expense is -10.83% of Operating Income.
  • The Net Earning history of AVTX is -1,639.50% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Avalo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AVTX
Website: avalotx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.42
Quick Ratio: 1.37

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

AVTX Technical Analysis vs Fundamental Analysis

Sell
31
Avalo Therapeutics (AVTX) is a Sell

Is Avalo Therapeutics a Buy or a Sell?